Sanofi says arbitration court rejects Boehringer’s Zantac claims

FRANKFURT: Sanofi said on Tuesday that the International Chamber of Commerce ruled in its favour in an arbitration case over claims by Boehringer Ingelheim that Sanofi should be liable for ongoing Zantac litigation in the United States.

The decision is final and can’t be appealed, the French drugmaker said in its statement.

Sanofi hones in on type 1 diabetes in $2.9bn Provention Bio deal

Boehringer said it had taken note of the arbitral tribunal’s decision and would not comment further.